Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 10/20 | 0.46 |
| ▸ | NOS1 | P29475 | 9/20 | 0.46 |
| ▸ | NOS3 | P29474 | 6/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CBFB | Q13951 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | WNT3A | P56704 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4866627 | 0.93 | NOS2 (0.46) | NOS2NOS1NOS3CYP2C9CBFB | |
| SCHEMBL4866623 | 0.87 | NOS2 (0.45) | NOS2NOS1NOS3CYP2C9AAK1 | |
| SCHEMBL4871273 | 0.86 | NOS2 (0.53) | NOS2NOS1NOS3CYP2C9AAK1 | |
| SCHEMBL4867936 | 0.86 | NOS2 (0.55) | NOS2NOS1NOS3CYP2C9 | |
| SCHEMBL4864599 | 0.83 | NOS2 (0.55) | NOS2NOS1NOS3CYP2C9AAK1 | |
| SCHEMBL4867989 | 0.82 | NOS2 (0.56) | NOS2NOS1NOS3CYP2C9 | |
| SCHEMBL4863062 | 0.80 | NOS2 (0.57) | NOS2NOS1NOS3CYP2C9 | |
| SCHEMBL4861099 | 0.79 | NOS2 (0.45) | NOS2NOS1NOS3CYP2C9CNR1 | |
| SCHEMBL5036512 | 0.76 | NOS2 (0.57) | NOS2NOS1NOS3CYP2C9FGFR3 | |
| SCHEMBL5033970 | 0.76 | NOS2 (0.67) | NOS2NOS1NOS3CYP2C9AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7390819-B2 | Imidazo[4,5-b]quinoline-derivatives and their use as no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2008-06-24 | — | — | US | claimed |
| EP-1599473-B1 | IMIDAZO 4,5-B QUINOLINE-DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS | ALTANA PHARMA AG (DE) | 2006-09-20 | — | — | EP | claimed |
| US-20060160839-A1 | Imidazo[4,5-b]quinoline-derivatives and their use as no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2006-07-20 | — | — | US | claimed |
| EP-1599473-A1 | IMIDAZO 4,5-B QUINOLINE-DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS | ALTANA Pharma AG (DE) | 2005-11-30 | — | — | EP | claimed |
| WO-2004076451-A1 | IMIDAZO[4,5-B]QUINOLINE-DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS | ALTANA PHARMA AG (DE) | 2004-09-10 | — | — | WO | claimed |
| US-7390819-B2 | Imidazo[4,5-b]quinoline-derivatives and their use as no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2008-06-24 | — | — | US | disclosed |
| EP-1599473-B1 | IMIDAZO 4,5-B QUINOLINE-DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS | ALTANA PHARMA AG (DE) | 2006-09-20 | — | — | EP | disclosed |
| EP-1599473-A1 | IMIDAZO 4,5-B QUINOLINE-DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS | ALTANA Pharma AG (DE) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004076451-A1 | IMIDAZO[4,5-B]QUINOLINE-DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS | ALTANA PHARMA AG (DE) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160839-A1 | Imidazo[4,5-b]quinoline-derivatives and their use as no-synthase inhibitors | NOS2, NOS1, NOS3 | NOS2 1/4885NOS1 2/4885NOS3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.